Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 2010;83:21–38. https://doi.org/10.1046/j.1365-2613.2002.00211.x.
Holloway SE, Beck AL, Shivakumar JS, Fleming JB, Brekken RA. Selective blockade of vascular endothelial growth factor receptor 2 with an antibody against tumor-derived vascular endothelial growth factor controls the growth of human pancreatic adenocarcinoma xenografts. Ann Surgical Oncol. 2006;13:1145–55. https://doi.org/10.1245/ASO.2006.05.049.
Siemann DW. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treat Rev. 2011;37:63–74. https://doi.org/10.1016/j.ctrv.2010.05.001.
CAS Article PubMed Google Scholar
Siemann DW, Horsman MR. Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacol Pharmacol Therapeutics. 2015;153:107–24. https://doi.org/10.1016/j.pharmthera.2015.06.006.
Steinmetz MO, Prota AE. Microtubule-targeting agents: strategies to hijack the cytoskeleton. Trends Cell Biol. 2018;153:107–24. https://doi.org/10.1016/J.tcb.2018.05.001.
Tozer GM, Akerman S, Cross NA, Barber PR, Bjorndahl MA, Greco O. et al. Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors. Cancer Res. 2005;5:423–35. https://doi.org/10.1158/0008-5472.
Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2021;9:790–803. https://doi.org/10.1038/nrd3253.
Yang CP, Susan H. Taxol: the first microtubule stabilizing agent. Int J Mol Sci. 2017;18:1733. https://doi.org/10.3390/ijms18081733.
CAS Article PubMed Central Google Scholar
Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev. 2009;35:255–61. https://doi.org/10.1016/j.ctrv.2008.11.001.
CAS Article PubMed Google Scholar
Desai A, Mitchison, T J. Microtubule polymerization dynamics. Annu Rev Cell Developmental Biol. 1997;13:83–117. https://doi.org/10.1146/annurev.cellbio.13.1.83.
Oakley BR. An abundance of tubulins. Trends Cell Biol. 2000;10:537–42. https://doi.org/10.1016/S0962-8924(00)01857-2.
CAS Article PubMed Google Scholar
Sharp DJ, Rogers GC, Scholey JM. Microtubule motors in mitosis. Nature. 2000;407:41–47. https://doi.org/10.1038/35024000.
CAS Article PubMed Google Scholar
Nam NH. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Medicinal Chem. 2003;10:1697–722. https://doi.org/10.2174/0929867033457151.
Jordan A, Hadfield JA, Lawrence NJ, Mcgown AT. Tubulin as a target for anticancer drugs: agents which interact with the mitotic spindle. Medicinal Res Rev. 1998;18:259–96. https://doi.org/10.1002/(sici)1098-1128(199807)18:4<259::aid-med3>3.0.co;2-u.
Jordan MA, Wilson A. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4:253–65. https://doi.org/10.1038/nrc1317.
CAS Article PubMed Google Scholar
Tron GC, Pirali T, Sorba G, Pagliai F, Busacca S, Genazzani AA. Medicinal chemistry of combretastatin A4: Present and future directions. J Medicinal Chem. 2006;49:3033–44. https://doi.org/10.1021/jm0512903.
Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer. 2005;5:423–35. https://doi.org/10.1038/nrc1628.
CAS Article PubMed Google Scholar
Cao WL, Zhang J, Tu XJ, Xu ZB, Wang M. Antiangiogenic activity research of the vascular endothelial growth factor receptor 2 extracellular region 3(KDR3). Yaowu Shengwu Jishu. 2013;20:203–6. https://doi.org/10.1016/j.pharmthera.2015.06.006.
Pettit GR, Cragg GM, Herald DL. Isolation and structure of combretastatin. Can J Chem. 1982;60:1374–6. https://doi.org/10.1139/v82-202.
Pettit GR, Singh SB. Isolation, structure, and synthesis of combretastatin A-2, A-3, and B-2. Can J Chem. 1987;65:2390–6. https://doi.org/10.1139/v87-399.
Pettit GR, Singh SB, Niven ML, Hamel E. Isolation, structure, and synthesis of combretastatin A-1 and B-1, potent new inhibitors of microtubule assembly, derived from combretum caffrum. J Nat Products. 1987;50:119–31. https://doi.org/10.1021/np50049a016.
Tozer GM, Kanthou C, Parkins CS, Hill SA. The biology of the combretastatins as tumour vascular targeting agents. Int J Exp Pathol. 2010;83:21–38. https://doi.org/10.1046/j.1365-2613.2002.00211.x.
Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res. 1999;19:189–95.
Karatoprak GE, Akkol EK, Gen Y, Bardakci H, Sobarzoz E. Combretastatins: an overview of structure, probable mechanisms of action and potential applications. Molecules. 2020;25:2560. https://doi.org/10.3390/molecules25112560.
CAS Article PubMed Central Google Scholar
Seddigi ZS, Malik MS, Saraswati AP, Ahmed S, Babalghith AO, Lamfon HA. et al. Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents. Medicinal Chem Commun. 2017;8:1592–603. https://doi.org/10.1039/c7md00227k.
Pettit GR, Singh SB, Hamel E, Lin CM, Alberts DS, Garcia KD. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia. 1989;45:209–11. https://doi.org/10.1007/BF01954881.
CAS Article PubMed Google Scholar
Greene LM, Meegan MJ, Zisterer DM. Combretastatins: more than just vascular targeting agents?. J Pharmacol Exp Therapeutics. 2015;355:217–27. https://doi.org/10.1124/jpet.115.226225.
Lawrence NJ, Hepworth LA, Rennison D, McGown AT, Hadfield JA. Synthesis and anticancer activity of fluorinated analogues of combretastatin A-4. Chehminform. 2003;123:101–8. https://doi.org/10.1002/chin.200402243.
Conforti F, Menichini F, Cachet X, Statti GA. Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin a-4. Curr Medicinal Chem. 2011;18:3035–81. https://doi.org/10.2174/092986711796391642.
Nam NH. Combretastatin A-4 analogues as antimitotic antitumor agents. Curr Medicinal Chem. 2003;10:1697–722. https://doi.org/10.2174/0929867033457151.
Bukhari SN, Kumar GB, Revankar HM, Qin HL. Development of combretastatins as potent tubulin polymerization inhibitors. Bioorg Chem. 2017;72:130–47. https://doi.org/10.1016/j.bioorg.2017.04.007.
CAS Article PubMed Google Scholar
Shan YS, Zhang J, Liu Z, Wang M, Dong Y. Developments of combretastatin A-4 derivatives as anticancer agents. Curr Medicinal Chem. 2011;18:523–38. https://doi.org/10.2174/092986711794480221.
Cushman M, He HM, Lin CM, Hamel E. Synthesis and evaluation of a series of benzylaniline hydrochlorides as potential cytotoxic and antimitotic agents acting by inhibition of tubulin polymerization. J Medicinal Chem. 1993;36:2817–21. https://doi.org/10.1021/jm00071a012.
Jaroch K, Karolak M, Gorski P, Jaroch A, Krajewski A, Ilnicka A. et al. Combretastatins: in vitro structure-activity relationship, mode of action and current clinical status. Pharmacol Rep. 2016;68:1266–75. https://doi.org/10.1016/j.pharep.2016.08.007.
CAS Article PubMed Google Scholar
Lin CM, Singh SB, Chu PS, Dempcy RO, Hamel E. Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol. 1988;34:200–8. https://doi.org/10.1016/0160-5402(88)90018-6.
CAS Article PubMed Google Scholar
Chaudhary A, Pandeya S, Kumar P, Sharma P, Gupta S, Soni N. et al. Combretastatin A-4 analogs as anticancer agents. Mini Rev Medicinal Chem. 2007;7:1186–205. https://doi.org/10.2174/138955707782795647.
Bukhari SN, Kumar GB, Revankar HM, Qin HL. Development of combretastatins as potent tubulin polymerization inhibitors. Bioorg Chem. 2017;72:130–47. https://doi.org/10.1016/j.bioorg.2017.04.007.
CAS Article PubMed Google Scholar
Edon V, David TS, Njardarson JT. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals. J Medicinal Chem. 2014;57:10257–74. https://doi.org/10.1021/jm501100b.
Chen J, Tao XF, Ying HZ. Recent development of colchicine binding site inhibitors. Chinese. J Mod Appl Pharm. 2011;28:824–30. CNKI:SUN:XDYD.0.2011-09-010.
留言 (0)